Skip to main content
. Author manuscript; available in PMC: 2021 Nov 4.
Published in final edited form as: Biotechnol J. 2021 Feb 11;16(6):e2000212. doi: 10.1002/biot.202000212

Figure 4.

Figure 4

Analysis of drug retention and in vitro drug release kinetics, as well as size, PDI and morphology upon using low amounts of cryoprotectants. The amount of free DTX plus 7-epi-DTX in reconstituted CPC634 cryoprotected with 10 wt% trehalose and sucrose as compared to non-freeze-dried/parental CPC634 control (A). DTX release profile of parental CPC634 formulation (control) and reconstituted CPC634 cryoprotected with trehalose and sucrose under physiological conditions (B). Sizes and PDI of reconstituted CPC634 cryoprotected with trehalose 5 wt% and 2.5 wt%, determined by DLS analysis (C, D). Values represent average ± SD of three different batches, measured in triplicates. Representative TEM images (E, F) of reconstituted CPC634 cryoprotected with 5 wt% and 2.5 wt% trehalose.